Navigation Links
Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076
Date:5/6/2013

dministration (CFDA) for ENMD-2076 to conduct global clinical trials in triple-negative breast cancer patients. 

About EntreMed

EntreMed is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer.  EntreMed is currently conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer and a Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma.  The Company is headquartered in Rockville, Maryland and has local operations in Beijing, China.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma, and is currently completing a Phase 2 trial for ovarian cancer.  EntreMed is currently conducting a dual-institutional
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
2. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
3. Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
4. Dr. Isaac Eliaz Awarded Patent for Modified Citrus Pectin and Alginates
5. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
6. LamdaGen Corporation Issued United States Patent for Diagnostics on Plasmonic-Based Nanosensors
7. Fuisz Pharma Announces Intent to Divest Strategic Patent for Detection of Opioid Abuse; Seeks Offers for Patent through May 2013
8. Bioinformatics Market: Technologies, Patenting Trends & 2017 Forecasts
9. Neuralstem Receives Notice Of Allowance Of Patent Covering Use Of Stem Cells To Treat Amyotrophic Lateral Sclerosis
10. VolitionRx Files Two Patent Applications
11. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
(Date:1/22/2015)... 22, 2015  Profil Institute for Clinical Research, Inc., a ... announced today a new textbook,  Translational Research Methods for ... a leading global scientific publisher. The textbook ... for use in early phase clinical studies of new ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... 4, 2011 Adherence to strict outcome requirements ... Services (CMS) has an adverse effect on liver ... than optimal conditions, according to researchers at Northwestern ... quality improvement initiatives aim to enhance post-transplant outcomes, ...
... OAKS, Calif. and NEW YORK, Nov. 5, 2011 Amgen ... PFE ) today announced results of the second and ... multi-center trial in patients with moderately active rheumatoid arthritis (RA) ... (LDA) or clinical remission on combination Enbrel® (etanercept) plus methotrexate ...
Cached Medicine Technology:Study Calls for Modification of CMS Conditions of Participation to Preserve Access to Life-Saving Liver Transplantations under Less than Optimal Conditions 2Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 2Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 3Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 4Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 5Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 6Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 7Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 8Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 9Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 10Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 11
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Recently, Weddingshe.com has ... catalog, and has announced its highest annual revenues in the ... on its popular glamorous wedding dresses. , According to the ... important wedding dress promotions for them in 2015. This point ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... component of overall health care gains momentum worldwide, Rev. ... York-based HealthCare Chaplaincy Network (HCCN), will be the ... advance spiritual care in Israel’s public health system. , The ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... Zimmer Holdings, Inc.,(NYSE ZMH; SWX: ZMH), a leader in ... following upcoming investor,conferences:, -- March 18, 2008 -- ... Massachusetts, 8:00 a.m. Eastern Time -- March 19, ... Conference, Miami Beach, Florida, 8:30 a.m. Eastern Time, ...
... The Campaign to Strengthen,Human Services, which is committed ... human service providers, today unveiled its,campaign website, ... social importance that human services providers bring to,all ... on passing Senate 65, a bill that would,establish ...
... survival rates, but one expert urges caution , , ... or specialized hospitals improved survival time for ovarian cancer ... the researchers examined data on 8,621 ovarian cancer patients ... those women, 40 percent were treated in general hospitals, ...
... also help, at least for a while, study finds, , , ... loss are often dismal, but a new study finds that ... they,re able to keep off more weight. , The ... were more likely to maintain their weight loss than people ...
... Nearly 8,000 nurses,and other healthcare workers in Ohio saw ... California Nurses Association flooded the state,with hostile organizers and ... calls urging them to vote against the union., ... an affiliate of the,AFL-CIO, the workers have for now ...
... Theres new evidence supporting the idea that bigger brains are ... the brainpower required to be dominant drives brain capacity. , ... in the brains of both males and females of one ... were also associated with being dominant. The study also ...
Cached Medicine News:Health News:New Human Services Website Details Economic Importance of Providers, Warns of Looming Crisis if System is Not Fixed Immediately 2Health News:Specialized Care for Ovarian Cancer Improves Outcomes 2Health News:Personal Contact Helps Maintain Weight Loss 2Health News:Personal Contact Helps Maintain Weight Loss 3Health News:SEIU: Thousands of Ohio Nurses and Other Healthcare Employees Denied a Voice at Work After Vicious Union-Busting Campaign by the California Nurses Association 2Health News:Which came first, social dominance or big brains? Wasps may tell 2Health News:Which came first, social dominance or big brains? Wasps may tell 3
... is designed to comfortably restrict motion ... unobstructed motion of the fingers and ... the splint may be trimmed using ... heat gun. One cotton stockinet is ...
FREEDOM® Memory Thumb Spica lets you make a custom splint in minutes. Immerese in 160 F water until pliable, and remove. Amazingly, it maintains its shape and is ready to be precisely, profession...
... QuickCast® Cast-like splints Slip ... dryer, and QuickCast conforms to ... cools. Reheat to adjust and ... coated with a temperature-sensitive polymer ...
... strong, the ThumSaver CMC Short lessens symptoms of ... and/or MP joints of the thumb. The ThumSaver ... IP joint motion for function. Includes felt padding ... and for rest due to repetitive stress injuries. ...
Medicine Products: